Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of vaccine therapy when given
with or without cyclophosphamide and to see how well they work in treating patients with
multiple myeloma that has come back (recurrent) or has not responded to previous treatment
(refractory). Vaccines made from a gene-modified virus may help the body build an effective
immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy
together with cyclophosphamide may be a better treatment for multiple myeloma.